CD274 and lung cancer: In 2015, FDA approved an immunohistochemical test for PD-L1 evaluation (28-8 pharmDx) in lung cancer treatment with nivolumab, and subsequently in 2016, a similar test (22C3 pharmDx) in melanoma treatment (it is also used in some clinical trials for patient recruitment; e.g., in NCT03829332 study).